Capital Fund Management (CFM)
AEGR

Capital Fund Management (CFM)’s Aegerion Pharmaceuticals AEGR Stock Holding History

Capital Fund Management (CFM)’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,900
Closed -$348K – 2094
2013
Q4 		$348K Buy
+4,900
New +$375K ﹤0.01% 1393

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Fund Management (CFM)'s AEGR Position: Q2 2015 in Review

Capital Fund Management (CFM) sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 15,900 shares — an estimated $416K sold.

Capital Fund Management (CFM) first reported a position in AEGR in Q4 2013 and held it in 3 quarters. The position peaked at $8.49M in Q4 2013. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • Capital Fund Management (CFM) reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 15,900 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $416K.
  • Capital Fund Management (CFM) first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Aegerion Pharmaceuticals position peaked at $8.49M in Q4 2013.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2015, filed 28 Jul 2015.